Potential Class Action Lawsuit for Tenax Therapeutics Investors - Deadline Approaches

Legal Action Looms for Tenax Therapeutics Investors

Investors of Tenax Therapeutics, Inc. (NASDAQ: TENX) should prepare for potential legal proceedings as substantial losses mark their investments. According to the law firm Robbins Geller Rudman & Dowd LLP, a window for lead plaintiff applications is closing on December 28, 2026. The class action, titled Katz v. Tenax Therapeutics, Inc., alleges serious violations of the Securities Exchange Act of 1934, implicating the company and some executives in deceptive practices that misled investors.

The Class Period Defined

Those who purchased or acquired Tenax securities between November 13, 2023, and August 7, 2026, are encouraged to act promptly. During this time frame, Tenax announced promising developments that led many to invest. The FDA had cleared their Investigational New Drug Application (IND) for the drug TNX-103, aimed at treating pulmonary hypertension related to heart failure with preserved ejection fraction. This announcement propelled many investors to acquire shares, believing they were making a sound financial decision.

Alarming Allegations

However, the lawsuit claims that the information disseminated by Tenax was misleading. It states that the company inflated the effectiveness of TNX-103, leading investors to believe that its clinical and regulatory prospects were far brighter than reality. The allegations further suggest that Tenax's public communications failed to reflect the drug’s true efficacy, thereby violating securities laws.

The turning point came on August 10, 2026, when Tenax reported its Phase 3 LEVEL trial results, revealing that TNX-103 did not achieve its primary endpoints. The announcement caused the stock price to plunge nearly 90%, leaving many investors in financial distress.

Becoming a Lead Plaintiff

Under the Private Securities Litigation Reform Act of 1995, investors who experienced significant losses and held securities during the class period can apply to be lead plaintiffs. This role is crucial, as it involves representing the interests of the entire class in the lawsuit. Lead plaintiffs will have the option to choose their legal representation, but their ability to recover financial losses does not hinge entirely on this position.

Interested parties can contact Robbins Geller representatives Ken Dolitsky or Michael Albert by phone or email to ensure they meet the deadline and complete the necessary documentation.

About Robbins Geller Rudman & Dowd LLP

Robbins Geller is highly regarded for its commitment to protecting investor rights, already securing over $916 million for investors in 2025 alone. With a substantial history of successful securities class action recoveries, the firm has nabbed the top spot in securities litigation across multiple years.

Their experience with high-stakes lawsuits provides investors with confidence as they navigate the complexities surrounding this recent turn of events involving Tenax Therapeutics.

If you are a Tenax investor affected by these developments, early action could be vital for your financial future. Don't let the opportunity for justice slip away; make sure to secure your position before the approaching deadline.